Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 0.95B P/E - EPS this Y 55.10% Ern Qtrly Grth -
Income -109.16M Forward P/E 191.69 EPS next Y 54.20% 50D Avg Chg -7.00%
Sales 264.38M PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 6.71 EPS next 5Y - 52W High Chg -18.00%
Recommedations 1.50 Quick Ratio 3.02 Shares Outstanding 47.71M 52W Low Chg 44.00%
Insider Own 2.21% ROA -12.27% Shares Float 35.91M Beta 1.15
Inst Own 118.08% ROE -70.98% Shares Shorted/Prior 7.05M/6.87M Price 24.92
Gross Margin 72.27% Profit Margin -41.29% Avg. Volume 536,962 Target Price 61.30
Oper. Margin -31.12% Earnings Date Oct 31 Volume 465,877 Change -0.20%
About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals, Inc. News
09:02 AM Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
07:30 AM Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
10/23/24 Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth
10/10/24 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/24 Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
10/09/24 Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ...
10/03/24 Exploring High Growth Tech Stocks In The US October 2024
09/06/24 Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
09/06/24 Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
08/29/24 High Growth Tech Stocks To Watch In August 2024
08/28/24 Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
08/19/24 Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
08/10/24 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
08/08/24 Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
08/07/24 Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
08/07/24 Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
03:30 PM Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
07/29/24 Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
07/25/24 Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
07/12/24 Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone
MIRM Chatroom

User Image LMXPERTEN Posted - 1 day ago

$MIRM q3 report - when?

User Image tradingtwenty Posted - 1 day ago

$MIRM $THAR has trended 36 times in the past 24 hours (based on 5 minute intervals). Latest press release on May 02, 2024 01:34 PM: Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management Link: https://tradingtwenty.com/news/456326/stonegate-healthcare-partners-updates-report-on-transformative-therapies-for-pruritus-management

User Image DrGonzo69 Posted - 3 days ago

$MIRM My fav pick atm. <3

User Image DrGonzo69 Posted - 1 week ago

I almost avgd-up on $MIRM $TARS instead of buying some $NTLA. oh well 😂

User Image GeniusLoci Posted - 1 week ago

$MIRM https://www.insidermonkey.com/blog/8-best-small-cap-growth-stocks-to-buy-according-to-analysts-1376646/4/

User Image LMXPERTEN Posted - 1 week ago

$MIRM now we are going into a phase where we could actually see wet-ink on paper. Up until now too little time and still early but at least we enter a period where this COULD potentially happen. I wouldnt stay outside at this stage.

User Image FannyPackin Posted - 1 week ago

$MIRM bought some January & April calls here today..

User Image swingingtech Posted - 2 weeks ago

$IRDM, $MIRM, $ST https://wallstreetwaves.com/significant-thursday-options-trends-irdm-mirm-st/

User Image Srinukala Posted - 2 weeks ago

$MIRM any update on this

User Image peloswing Posted - 2 weeks ago

Tomorrow is the FDA action date for Intercept Pharmaceuticals' Ocaliva. The decision could have implications for Mirum Pharmaceuticals $MIRM 🚨

User Image Doozio Posted - 2 weeks ago

$MIRM tightness bahhhtom of da first base above da $$$ as da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️

User Image GeniusLoci Posted - 3 weeks ago

$MIRM CP Updated https://s29.q4cdn.com/633867992/files/doc_presentations/2024/Oct/10/Mirum-Updated-Corporate-Presentation_Oct-Update.pdf

User Image Theflash88 Posted - 3 weeks ago

$MIRM Mirum’s liver disease drug candidate gets FDA breakthrough designation Oct. 10, 2024 10:10 AM ETMirum Pharmaceuticals, Inc. (MIRM) StockBy: Preeti Singh, SA News Editor

User Image DonCorleone77 Posted - 3 weeks ago

$MIRM Mirum Pharmaceuticals granted Breakthrough Therapy Designation for volixibat Mirum Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis, or PBC. The regulatory designation is based on the interim analysis of the Phase 2b VANTAGE study which showed statistically significant improvement versus placebo in pruritus for patients treated with volixibat. The confirmatory portion of the study is ongoing with completion of enrollment expected in 2026.

User Image DrGonzo69 Posted - 3 weeks ago

$MIRM waiting to AVG up, might just buy some more at these levels, don't want to miss out 😁

User Image sunset_PARK Posted - 4 weeks ago

$MIRM a director just donated appx 100 thousand shares to the children's hospital of Philadelphia foundation. Worth more than 4m dollars

User Image LMXPERTEN Posted - 4 weeks ago

$MIRM 🌳 has been shaken

User Image DrGonzo69 Posted - 4 weeks ago

$MIRM holding so well.

User Image LMXPERTEN Posted - 1 month ago

$MIRM pending BO

User Image Gatorgunk Posted - 1 month ago

$CAPR $MIRM is a company with a therapy for a rare liver disease that market is only 100s of patients yearly. They’re close to $2B market cap. Our market is exponentially bigger in dmd alone.

User Image LMXPERTEN Posted - 1 month ago

$MIRM as I said many times before. Milestones parade is dead. Only a BO can save the co now. Of course, SOBI and others know this. The best in the future but mid or long term from now. Impatient investors might accept a real sh-t bid. Most of these investors are amateurs and do not understand Clin dev, MAA nor life cycle mgt. This is a 💎

User Image valueforme Posted - 1 month ago

$MIRM I'm upset to see the open market tiny insider buy at this point. What did this Frazier guy want to say with his 115 shares buy? No deal yet, relax? https://www.sec.gov/Archives/edgar/data/1759425/000141588924023777/xslF345X05/form4-09202024_080957.xml

User Image insiderbuyingselling Posted - 1 month ago

$MIRM new insider buying: 115 shares. http://insiderbuyingselling.com/?t=MIRM

User Image fda_tracker Posted - 1 month ago

$MIRM Phase 3 trial w/est Sep completion date NCT04185363: https://www.clinicaltrials.gov/study/NCT04185363 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image KyleProfitGuardA Posted - 1 month ago

$MIRM

User Image KyleProfitGuardA Posted - 1 month ago

$MIRM

User Image CH_Expat Posted - 1 month ago

$MIRM @valueforme @WSRX Thank you for bringing this back to my mind, now I am super tempted to jump back in despite this is my basic rule to never chase the running train I missed.

User Image CH_Expat Posted - 1 month ago

@WSRX @valueforme I never entered MIRM, waited for 23 that never came back. I was in ALBO back then. Made my biggest mistakes chasing stocks I missed, so I will wait here. Gut feeling is something is about to happen at $MIRM

User Image valueforme Posted - 1 month ago

$MIRM Radovich established this Rule 10b5-1 in March 2024, Peetz in December 2023. And then suddenly both terminate 10b5-1 days after Vistas and Vantage readouts. This reminds me of a similar setup in Tarsus

User Image valueforme Posted - 1 month ago

$MIRM The connection between Sobi and Mirum.

Analyst Ratings
Cantor Fitzgerald Overweight Aug 8, 24
Evercore ISI Group Outperform Aug 8, 24
Baird Outperform Aug 8, 24
HC Wainwright & Co. Buy Jul 26, 24
HC Wainwright & Co. Buy Jul 8, 24
HC Wainwright & Co. Buy Jun 28, 24
Stifel Buy Jun 20, 24
Citigroup Buy Jun 18, 24
JP Morgan Overweight Jun 18, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Vig Pamela CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Feb 02 Sell 26.1918 1,214 31,797 28,691 02/05/24
Longpre Lara CHIEF DEVELOPMENT OF.. CHIEF DEVELOPMENT OFFICER Feb 02 Sell 26.1918 847 22,184 104,407 02/05/24
Radovich Peter PRESIDENT AND COO PRESIDENT AND COO Feb 02 Sell 26.1917 1,790 46,883 34,695 02/05/24
Peetz Christopher CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 02 Sell 26.1918 6,013 157,491 104,112 02/05/24
Howe Jolanda SVP, GLOBAL CONTROLL.. SVP, GLOBAL CONTROLLER Jan 31 Sell 26.19 735 19,250 1,759 02/02/24
Radovich Peter CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER Jan 08 Sell 28.0345 1,408 39,473 36,485 01/09/24
Longpre Lara CHIEF DEVELOPMENT OF.. CHIEF DEVELOPMENT OFFICER Jan 08 Sell 28.0350 1,019 28,568 105,254 01/09/24
Vig Pamela HEAD OF RESEARCH & D.. HEAD OF RESEARCH & DEVELOPMENT Jan 08 Sell 28.0343 1,408 39,472 29,905 01/09/24
Peetz Christopher PRESIDENT AND CEO PRESIDENT AND CEO Jan 08 Sell 28.0348 5,209 146,033 110,125 01/09/24
Howe Jolanda SVP, GLOBAL CONTROLL.. SVP, GLOBAL CONTROLLER Jan 06 Sell 28.04 528 14,805 722 01/09/24
Howe Jolanda SVP, Global Controll.. SVP, Global Controller Dec 05 Option 2.94 2,500 7,350 2,500 12/06/23
Howe Jolanda SVP, Global Controll.. SVP, Global Controller Dec 05 Sell 32.4 2,500 81,000 12/06/23
GREY MICHAEL G Director Director Sep 13 Sell 32 14,608 467,456 09/14/23
GREY MICHAEL G Director Director Sep 13 Option 2.94 14,608 42,948 14,216 09/14/23
BJERKHOLT ERIC Chief Financial Offi.. Chief Financial Officer Sep 11 Buy 29.6492 10,000 296,492 10,000 09/12/23
Heron Patrick J Director Director Aug 31 Buy 26.25 147,991 3,884,764 147,991 09/05/23
Radovich Peter Chief Operating Offi.. Chief Operating Officer Jul 03 Sell 25.6466 1,425 36,546 37,675 07/05/23
Longpre Lara Chief Development Of.. Chief Development Officer Jul 03 Sell 25.6466 1,004 25,749 105,839 07/05/23
GREY MICHAEL G Director Director May 03 Sell 28 14,608 409,024 05/04/23
GREY MICHAEL G Director Director May 03 Option 2.94 14,608 42,948 14,608 05/04/23
O'Donnell Niall Director Director Nov 11 Sell 19.76 300,000 5,928,000 1,621,118 11/15/22
Flynn James E - - Jun 06 Sell 24.95 38,478 960,026 1,540,190 06/08/22
Clements Ian Chief Financial Offi.. Chief Financial Officer Nov 24 Buy 14.15 1,450 20,518 18,561 11/29/21